Importantly, PCa patients with high CD51 levels displayed a much worse clinical outcome, with a median progression-free survival (PFS) of 20 months compared to 24 months for CD51-negative patients (hazard ratio (HR), 0.379; 95% CI, 0.1592–0.9036; p = 0.028) (Fig. 1d). The gene discussed is ITGAV; the disease is posterior cortical atrophy.